XSpray Pharma AB
The answer first
Does XSpray Pharma beat the market?
No, XSpray Pharma has not beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 23% of Nordic stocks
- Quality71
- Value18
- Trend22
No. 123 of 195 in healthcare
Max for seven days
Follow XSpray Pharma with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about XSpray Pharma
Your first answer is free, no account needed.
Do you own XSpray Pharma, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with XSpray Pharma and a few more. Free, no card.
Super Stock+44.6%In short
- XSpray Pharma has fallen 55.3% over the past year, including dividends.
- Overall, XSpray Pharma ranks better than 23% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 89.0%. The price is 95.5% below its peak now.
What do analysts think of XSpray Pharma?
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 23% of Nordic stocks.
No. 123 of 195 in healthcare
High A solid company: it earns well on its money and has healthy finances.
No. 82 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.41
- Asset turnoverSales divided by everything the company owns0.00
- Return on equityProfit divided by equity−25.3%
- Cash conversionOperating cash flow divided by profit–
The ranking is built on equity ratio, ROA and how steadily profit grows.
Low High price: buyers pay a lot today, often because they expect growth.
No. 107 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50
- P/BPrice divided by equity0.9
- P/SPrice divided by sales82.1
- P/EPrice divided by earningsnegative earnings
- P/CFPrice divided by operating cash flownegative earnings
The ranking is built on P/E, P/B and P/S.
Low Headwind in the share price: it has done worse than most over the last year.
No. 119 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months+4.2%
- 6 months−54.8%
- 9 months−58.2%
- 12 months−55.3%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
The funds that own XSpray Pharma
4 funds we follow own XSpray Pharma. The share is how much of the fund the stock makes up.
- Sweden4
From the funds' latest known holdings.
About XSpray Pharma
XSpray Pharma AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 24 employees.
Xspray Pharma AB (publ), a pharmaceutical company, engages in the development of protein kinase inhibitors for targeted cancer treatments in Sweden. The company develops Dasynoc, an amorphous version of dasatinib for the treatment of chronic myeloid leukemia (CML)and acute lymphoblastic leukemia; XS003, an amorphous non-crystalline nilotinib for the treatment of CML; XS008, an axitinib for the treatment of kidney cancer; and XS025, a amorphous non-crystalline cabozantinib for the treatment of renal cell carcinoma and other cancers. It has partnership agreements with EVERSANA for the commercialization of Dasynoc.


See the full analysis of XSpray Pharma.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card